18F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Apply measurability criteria based on the response evaluation criteria in solid tumors (RECIST) to lesions found on 18F-choline positron emission tomography (PET)/computerized tomography (CT) in patients with hormone refractory prostate cancer.
Whole-body PET followed by CT or in-line PET/CT using 3.3–4 MBq/kg of 18F-choline was performed prospectively on 30 patients with prostate cancer, castrate testosterone levels, and rising post-treatment prostate specific antigen (PSA) levels. Lesions demonstrating increased 18F-choline uptake were classified as measurable or non-measureable based on RECIST.
Three patients were known previously to have RECIST measurable lesions, 10 patients had metastatic findings on radionuclide bone scan, and 17 patients had elevated serum PSA level as the only evidence of disease. Lesions demonstrating increased 18F-choline uptake were found in 28 (93%) patients. Thirty-eight PET/CT lesions from 14 patients were measurable by RECIST. Lymph node maximum standardized uptake value (SUVmax) correlated with lymph node diameter (Pearson r = 0.44, p < 0. 001). RECIST measurable lymph node SUVmax was significantly higher than that of non-measurable nodes (8.1 vs. 3.7, p < 0.0001). Detection of skeletal, prostatic, or RECIST-compatible lesions was more likely with a PSA level greater than 4.0 ng/ml (Fisher exact p = 0.0005).
Lesions detected with 18F-choline PET/CT are frequently measurable by RECIST at baseline. Therefore, it may be feasible to include comparisons to RECIST in evaluations of 18F-choline as a therapeutic response marker for hormone refractory prostate cancer.
- Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20. doi:10.1056/NEJMoa041318. CrossRef
- Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12. doi:10.1056/NEJMoa040720. CrossRef
- Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: “RECIST”ing a step backwards. Clin Cancer Res. 2005;11(14):5223–32. doi:10.1158/1078-0432.CCR-05-0109. CrossRef
- Swindle PW, Kattan MW, Scardino PT. Markers and meaning of primary treatment failure. Urol Clin North Am. 2003;30(2):377–401. doi:10.1016/S0094-0143(02)00176-3. CrossRef
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16. doi:10.1093/jnci/92.3.205.
- Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004;64(12):4270–6. doi:10.1158/0008-5472.CAN-03-3829. CrossRef
- Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002;296(3):580–3. doi:10.1016/S0006-291X(02)00920-8. CrossRef
- Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol. 2006;8(1):43–8. doi:10.1007/s11307-005-0023-2. CrossRef
- Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med. 2007;37(6):420–8. doi:10.1053/j.semnuclmed.2007.07.003. CrossRef
- Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168(1):273–80. doi:10.1016/S0022-5347(05)64906-3. CrossRef
- DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61(1):110–7.
- Lim J, Dorman E, Cabral C. Automated production of[18F]FECh and [18F]FCH: preparation and use of [18F]Fluoroalkane sulfonates and fluoroalkylation agents. J Labelled Comp Radiopharm. 2003;46:S46. doi:10.1002/jlcr.757.
- Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med. 2007;48(3):471–80.
- Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 2005;173(1):252–5.
- Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006;47(2):262–9.
- Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148–59. doi:10.1200/JCO.2007.12.4487. CrossRef
- Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol. 2006;176(5):2014–8. discussion 2018–2019. doi:10.1016/j.juro.2006.07.037.
- Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(2):253–63. doi:10.1007/s00259-007-0552-9. CrossRef
- Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35(10):1766–74. doi:10.1007/s00259-008-0788-z. CrossRef
- Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int. 2007;99(6):1415–20. doi:10.1111/j.1464-410X.2007.06772.x. CrossRef
- Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate. 2005;65(2):178–87. doi:10.1002/pros.20280. CrossRef
- Yeh SD, Imbriaco M, Larson SM, Garza D, Zhang JJ, Kalaigian H, et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol. 1996;23(6):693–7. doi:10.1016/0969-8051(96)00044-3. CrossRef
- Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996;199(3):751–6.
- Nunez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med. 2002;43(1):46–55.
- Zhang Y, Saylor M, Wen S, Silva MD, Rolfe M, Bolen J, et al. Longitudinally quantitative 2-deoxy-2-[18F]fluoro-d-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model. Mol Imaging Biol. 2006;8(5):300–8. doi:10.1007/s11307-006-0052-5. CrossRef
- Morris MJ, Akhurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005;11(9):3210–6. doi:10.1158/1078-0432.CCR-04-2034. CrossRef
- 18F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer
Annals of Nuclear Medicine
Volume 23, Issue 6 , pp 541-548
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Positron emission tomography
- Prostate carcinoma
- Industry Sectors